Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT

Bone Marrow Transplantation

Volumn 48, Issue 1, 2013, Pages 50-55

  Porkholm, M ^a   Bono, P ^b   Saarinen Pihkala, U M ^a   Kivivuori, S M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Angiopoietin 2; Hematopoietic SCT; Pediatric; VEGF

Indexed keywords

ANGIOPOIETIN 2; VASCULOTROPIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SCHOOL CHILD; SURVIVAL TIME;

ANGIOPOIETIN-2; CHILD; FEMALE; FINLAND; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS, PEDIATRIC; HOSPITALS, UNIVERSITY; HUMANS; INTESTINAL DISEASES; LIVER DISEASES; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872144998     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.101     Document Type: Article

References (22)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
2. Li WW, Hutnik M, Gehr G. Antiangiogenesis in haematological malignancies. Br J Haematol 2008; 143: 622-631.
3. Mirshahi P, Rafii A, Vincent L, Berthaut A, Varin R, Kalantar G et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 2009; 23: 1039-1048.
4. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005; 105: 1383-1395. (Pubitemid 40223651)
5. Hu B, Cheng SY. Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep 2009; 11: 111-116.
6. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004; 10: 813-815. (Pubitemid 39070853)
7. Lunn RA, Sumar N, Bansal AS, Treleaven J. Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematol 2005; 10: 107-114. (Pubitemid 41800784)
8. Min CK, Kim SY, Lee MJ, Eom KS, Kim YJ, Kim HJ et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 149-156.
9. Penack O, Socie G, van den Brink MR. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood 2011; 117: 4181-4189.
10. Kivivuori SM, Siitonen S, Porkka K, Vettenranta K, Alitalo R, Saarinen-Pihkala U. Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells. Pediatr Blood Cancer 2007; 48: 387-392. (Pubitemid 46340102)
11. Hu SW, Cotliar J. Acute graft-versus-host disease following hematopoietic stemcell transplantation. Dermat Ther 2011; 24: 411-423.
12. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39. (Pubitemid 8018922)
14. Nachbaur D, Schumacher P, Auberger J, Clausen J, Kircher B. Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 942-947. (Pubitemid 47055385)
15. Kim DH, Lee NY, Lee MH, Sohn SK. Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 1408-1416.
16. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956-964. (Pubitemid 28101786)
17. Hou HA, Chou WC, Lin LI, Tang JL, Tseng MH, Huang CF et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 2008; 32: 904-912.
18. Kumpers P, Koenecke C, Hecker H, Hellpap J, Horn R, Verhagen W et al. Angiopoietin-2. predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 2008; 112: 2139-2148.
19. Nomura S, Ishii K, Inami N, Kimura Y, Uoshima N, Ishida H et al. Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 766-774. (Pubitemid 351773153)
20. Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118: 1685-1692.
21. Pavlakovic H, Von Schutz V, Rossler J, Koscielniak E, Havers W, Schweigerer L. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 2001; 92: 756-760. (Pubitemid 32385721)
22. Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 2004; 103: 2929-2935. (Pubitemid 38451662)